Zenas BioPharma (ZBIO) Fundamentals 2026 — Revenue Analysis | SniperIQ
Zenas BioPharma (ZBIO) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zenas BioPharma's market cap?
Zenas BioPharma (ZBIO) has a market capitalization of approximately
What is Zenas BioPharma's P/E ratio?
Zenas BioPharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zenas BioPharma?
Zenas BioPharma runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zenas BioPharma generate?
Zenas BioPharma reported revenue of
Does Zenas BioPharma pay a dividend?
Zenas BioPharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Zenas BioPharma financially healthy?
Zenas BioPharma carries a debt-to-equity ratio of 1.05x and a current ratio of 11.94x, with a market beta of -0.94. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zenas BioPharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zenas BioPharma (ZBIO) the key facts are: market cap
Track Zenas BioPharma's full fundamentals live
Get Zenas BioPharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.